News
Hosted on MSN6mon
Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status EpilepticusIn the RAISE trial, patients were randomized to receive either IV ganaxolone or a placebo, alongside standard care. One of the trial’s co-primary endpoints—cessation of status epilepticus (SE ...
DELCO Today on MSN1y
Marinus Pharmaceuticals Loses 80 Percent Market Value Over New DrugMarinus Pharmaceuticals of Radnor saw its stock price plunge by more than 80 percent Monday because of a setback in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback